Total
0
Shares
MRC and University of Adelaide create methods to produce Graphene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Invex Therapeutics (IXC) is reviewing its upcoming Presendin hypertension treatment trial after receiving feedback from the US Food and Drug Administration
  • The FDA recommended Invex consider more "clinically meaningful" measures as primary endpoints for the planned phase three trial
  • Invex is determining a new direction for the study following the advice, which the company says is at odds with feedback from the European Medicines Agency (EMA)
  • Invex Therapeutics Chairman Dr Jason Loveridge says the submissions had sought to gain a broad consensus between the EMA and FDA
  • Invex Therapeutics shares are down 16 per cent to trade at 55 cents

Invex Therapeutics (IXC) is reviewing its upcoming Presendin hypertension treatment trial after receiving feedback from the US Food and Drug Administration.

Invex sought the FDA’s guidance on the overall study design and its suggestion that intracranial pressure and headache be key endpoints for the trial.

In its feedback, the US federal agency recommended Invex consider a more "clinically meaningful" effect on visual function when measuring a change in the patient's vision as a primary endpoint for the trial.

Further to this, the FDA said it considered intracranial pressure as an appropriate secondary endpoint of a study, but not a primary endpoint that would support approval of Presendin in Idiopathic Intracranial Hypertension (IIH).

Invex said the advice contrasted with feedback from the European Medicines Agency (EMA), which considered lowered intracranial pressure as an appropriate primary endpoint for the study.

The company said it intends to meet with its regulatory and clinical advisors in the coming weeks to determine the next direction for the phase three study.

Invex Therapeutics Chairman Dr Jason Loveridge said its submissions had sought to gain a broad consensus between the EMA and FDA.

"In its response, the Division of Neurology repeated the original Division of Ophthalmology feedback that visual function should be a key outcome measure of a study seeking approval of a drug for the treatment of IIH in the US," he said.

Invex Therapeutics shares were down 16 per cent to trade at 55 cents at 11:31 am AEST.

IXC by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.